Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia

Acute Leukemia Committee of the CIBMTR, Partow Kebriaei, Claudio Anasetti, Mei Jie Zhang, Hai Lin Wang, Ibrahim Aldoss, Marcos de Lima, H. Jean Khoury, Brenda M. Sandmaier, Mary M. Horowitz, Andrew Artz, Nelli Bejanyan, Stefan Ciurea, Hillard M. Lazarus, Robert Peter Gale, Mark Litzow, Christopher Bredeson, Matthew D. Seftel, Michael A. Pulsipher, Jaap Jan Boelens & 31 others Joseph Alvarnas, Richard Champlin, Stephen Forman, Vinod Pullarkat, Daniel Weisdorf, David I. Marks, William Hogan, Minoo Battiwalla, Edward Copelan, Gerhard Hildebrandt, Sid Ganguly, Navneet Majhail, Ann Woolfrey, Ian Nivison-Smith, Mark Hertzberg, Miguel Angel Diaz, Ann Jakubowski, Celalettin Ustun, Agnes Yong, Cesar Freytes, Zachariah DeFilipp, Yoshi Inamoto, Jean Yves Cahn, Bipin Savani, Jean Yared, Ashish Bajel, Ulrike Bacher, Geoffrey Uy, David Rizzieri, Matthew Wieduwilt, Kirk Schultz

Research output: Contribution to journalArticle

11 Citations (Scopus)


Total body irradiation (TBI) has been included in standard conditioning for acute lymphoblastic leukemia (ALL) before hematopoietic cell transplantation (HCT). Non-TBI regimens have incorporated busulfan (Bu) to decrease toxicity. This retrospective study analyzed TBI and Bu on outcomes of ALL patients 18–60 years old, in first or second complete remission (CR), undergoing HLA-compatible sibling, related, or unrelated donor HCT, who reported to the Center for International Blood and Marrow Transplant Research from 2005 to 2014. TBI plus etoposide (25%) or cyclophosphamide (75%) was used in 819 patients, and intravenous Bu plus fludarabine (41%), clofarabine (30%), cyclophosphamide (15%), or melphalan (13%) was used in 299 patients. Bu-containing regimens were analyzed together, since no significant differences for patient outcomes were noted between them. Bu patients were older, with better performance status; took longer to achieve first CR and receive HCT; were treated more recently; and were more likely to receive peripheral blood grafts, antithymocyte globulin, or tyrosine kinase inhibitors. With median follow-up of 3.6 years for Bu and 5.3 years for TBI, adjusted 3-year outcomes showed treatment-related mortality Bu 19% versus TBI 25% (P =.04); relapse Bu 37% versus TBI 28% (P =.007); disease-free survival (DFS) Bu 45% versus TBI 48% (P =.35); and overall survival (OS) Bu 57% versus TBI 53% (P =.35). In multivariate analysis, Bu patients had higher risk of relapse (relative risk, 1.46; 95% confidence interval, 1.15 to 1.85; P =.002) compared with TBI patients. Despite the higher relapse, Bu-containing conditioning led to similar OS and DFS following HCT for ALL.

Number of pages8
JournalBiology of Blood and Marrow Transplantation
Issue number4
Publication statusPublished - 1 Apr 2018


  • Acute lymphoblastic leukemia
  • Allogeneic transplant
  • Busulfan
  • Total body irradiation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this